Since our study reveals that zoledronic acid promotes ferroptosis through decreasing cellular CoQ10 level, which is independent from the inhibition of GPX4 by RSL3, this explains the additive inhibitory effects of combining these two drugs on the growth of osteosarcoma cells. Here, GPX4 is linked to osteosarcoma.